The purpose of this study is to estimate the direct costs associated with switching, in either direction, between a rapid-acting analog therapy and short-acting human insulin therapy within the first year following the switch. The additional goals are: 1)to assess the impact of a switch from or to a rapid-acting analog insulin therapy on patient treatment satisfaction, 2) to assess the impact of a switch from or to a rapid-acting analog insulin therapy on patient quality of life, 3) to assess the impact of switch from or to the rapid-acting analog insulin therapy on the quality of metabolic control and, 4) to estimate the total costs (direct and indirect) associated with switching, in either direction between rapid-acting analog and short-acting human insulin within the first year following the switch.

Inclusion Criteria:

• are at least 18 years of age
• according to the clinical judgement of the investigator have been diagnosed with type II diabetes
• have presented within the normal course of care
• at the baseline visit are being treated with any therapy including a rapid-acting analog insulin component or any therapy including a short-acting human insulin component and are switching from one form of therapy to the other
• are not simultaneously participating in a study that includes an investigational drug or procedure at entry into the study
• have been fully informed and have given their written consent for the use of their data
• have a sufficient understanding of the primary language of the country such that they will be able to complete the questionnaires

Exclusion Criteria:

• no specific exclusion criteria exist for this study

Patients with Type II Diabetes treated with a regimen which includes any rapid-acting analog insulin or any short-acting human insulin